Procedural Discomfort Related to Number of Intradetrusor Botox Injections (BIND)
Overactive Bladder
About this trial
This is an interventional treatment trial for Overactive Bladder focused on measuring Overactive bladder, Urinary urgency, Urgency incontinence, Botox
Eligibility Criteria
Inclusion Criteria: Women scheduled to undergo 100 units intradetrusor BTX-A injections in the office for the diagnosis of idiopathic overactive bladder within the departments of Urology and Urogynecology 18 years of age or older Able to give informed consent in English or Spanish Understand and are willing to undergo follow-up and complete all questionnaires as described in this protocol Exclusion Criteria: Neurogenic bladder related to prior diagnosis of neurological conditions such as cerebral vascular accident within 6 months prior to treatment, Parkinson's Disease, Multiple Sclerosis, myelomeningocele, traumatic neurologic or spinal injury, or idiopathic diagnosis of neurogenic bladder. Symptomatic UTI at the time of procedure, defined as positive nitrites or high-volume leukocyte esterase on urine dip in addition to at least one of the following symptoms: dysuria, gross hematuria, suprapubic pain, frequency/urgency above baseline Diagnosis of a bladder pain syndrome or other chronic pain syndromes including fibromyalgia, chronic pelvic pain, pelvic floor dysfunction, levator myalgia Known bladder malignancy Previous history of bladder augmentation or reconstructive surgery not related to prolapse
Sites / Locations
- Houston Methodist HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
5 mL Group
10 mL Group
100 units BTX-A reconstituted in 5 mL normal saline, injected into the bladder in 5 separate injections of 1 mL. One injection will be at the trigone.
100 units BTX-A reconstituted in 10 mL normal saline, injected into the bladder in 10 separate injections of 1 mL. One injection will be at the trigone